

15 September 2025

Lenalidomide Viatris (lenalidomide) Capsules - NZ-Specific Cartons

Dear Healthcare Professional,

We are writing to provide you of an important update regarding Lenalidomide Viatris (lenalidomide) Capsules (provisional consent) sponsored by Viatris Ltd.

All marketed strengths of Lenalidomide Viatris (5 mg, 10 mg, 15 mg, and 25 mg) have had the existing cartons updated to include a red box warning for the dispensing pharmacists. The product will be switching over to this new carton.

The additional wording added to the cartons is a reminder to pharmacists to check the authorisation code and pregnancy status of the patient (as applicable) before dispensing using Viatris Care program accessible via https://www.viatriscare.co.nz/

There are some minor updates to how the information is expressed on the carton and foil. There is no change to the formulation.

The updated cartons are expected to be in the New Zealand marketplace from late September 2025.

Images of the Existing and New cartons are provided in the table below.

Healthcare professionals are advised to refer to the approved New Zealand Data Sheet when prescribing Lenalidomide Viatris, accessible here: https://www.medsafe.govt.nz/

Adverse Event Reporting & Medical Enquiries

Please report any suspected adverse events via email to Medinfo anz@viatris.com. Alternatively, suspected adverse events may be reported to the Centre for Adverse Reactions Monitoring (CARM) online at https://pophealth.my.site.com/carmreportnz/s/ reporting or by email to CARMreport@health.govt.nz. Please direct any medical enquiries to Viatris or report any suspected adverse drug reactions to Viatris via telephone on 0800 168 169 or by email at medinfo anz@viatris.com.

Yours Sincerely,

Manar Al-Murrani

Senior Medical Affairs Specialist


Manar Al-Murrani



Summary of the Updates

Carton Overview

NZ-specific carton



MA-NZ-Haematology-09/25-00001